The first preclinical confirmations for antiseizure effects of racemic fenfluramine in models of Dravet syndrome came from pharmacological analysis in an antisense knockdown zebrafish model and an scn1a mutant zebrafish model.131, 132. Here, SCN1A is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.